---
title: "H.C. Wainwright Keeps Their Buy Rating on Helus Pharma (HELP)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284426300.md"
description: "H.C. Wainwright analyst Patrick Trucchio has maintained a Buy rating on Helus Pharma (HELP) with a price target of $95.00. Trucchio, a 5-star analyst with a 27.2% average return, reports that the consensus on Helus Pharma is a Strong Buy, with an average price target of $41.17. He also covers other healthcare stocks like Atai Beckley N.V. and Immunocore Holdings."
datetime: "2026-04-28T16:35:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284426300.md)
  - [en](https://longbridge.com/en/news/284426300.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284426300.md)
---

# H.C. Wainwright Keeps Their Buy Rating on Helus Pharma (HELP)

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Helus Pharma, with a price target of $95.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Trucchio is a 5-star analyst with an average return of 27.2% and a 52.24% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Atai Beckley N.V., Definium Therapeutics, and Immunocore Holdings.

Currently, the analyst consensus on Helus Pharma is a Strong Buy with an average price target of $41.17.

### Related Stocks

- [HELP.US](https://longbridge.com/en/quote/HELP.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ATAI.US](https://longbridge.com/en/quote/ATAI.US.md)
- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)
- [IMCR.US](https://longbridge.com/en/quote/IMCR.US.md)
- [CYBN.US](https://longbridge.com/en/quote/CYBN.US.md)

## Related News & Research

- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)